PTSD

The FDA instead issued a CRL for MDMA-assisted psychotherapy for PTSD, requesting an additional phase 3 trial to examine safety and efficacy. Other psychedelic compounds are proceeding with trials for psychiatric conditions. Learn more here.

Learn more about the latest research related to 9/11 trauma and other psychiatric comorbidities.

While new treatment options in the PTSD space can be exciting, we cannot lose sight of the treatments that are already readily available.

In this CME article, learn more about how to assess the impact of alcohol and cannabis use on anxiety treatment outcomes, recognizing potential adverse effects and interactions.

Is PTSD overdiagnosed?

A phase 3 clinical trial participant shares her thoughts on MDMA-assisted psychotherapy and her trial experience.

Despite the FDA's complete response letter for MDMA-assisted psychotherapy, researchers believe the data behind this PTSD treatment is what matters most.

How can you best identify and manage pediatric PTSD?

At least 1 in 2 people experience trauma at some point in their life, and a subset of those individuals will develop PTSD.

Whether a patient has a diagnosis of cPTSD, BPD, or some combination of both, treatment should be considered multifaceted and overlapping. Learn more in this Special Report article.

An understanding of evolving risk factors and pathophysiology is vital to optimal clinical management of anxiety disorders and PTSD.

For those who have experienced trauma and suffer a subsequent mental health disorder, ongoing research is identifying psychotherapies, medications, and lifestyle changes that can help.

The 2024 American Society of Clinical Psychopharmacology Annual Meeting brought together researchers and clinicians to engage in discussion, education, and dissemination of research findings and new methodologies.

The FDA did not vote to deny approval of MDMA-assisted psychotherapy on June 4, 2024, contrary to all the buzz in the media saying they did. Learn more here.

Psychiatric Times wants to help you, as clinicians, support every patient.

Prepare your patients for the Fourth of July with expert tips from Roger Rivera, FNP, PMHNP, DNP, on managing risky behaviors, adherence distractions, PTSD-related triggers, and sensory overload during the holiday.

June held negative news for psychedelics and an accepted sNDA for brexpiprazole + sertraline for adults with PTSD.

Here are highlights from the week in Psychiatric Times.

Following the vote of the US Food and Drug Administration Psychopharmacologic Drugs Advisory Committee, Lykos has released a statement on MDMA-assisted therapy.

Here are highlights from the week in Psychiatric Times.

Psychiatric Times Editor-in-Chief shares his thoughts on the FDA Psychopharmacologic Drugs Advisory Committee decision for MDMA.

The FDA Psychopharmacologic Drugs Advisory Committee voted against recommending approval for psychedelic MDMA.

The FDA Meeting of the Psychopharmacologic Drugs Advisory Committee evaluating the New Drug Application for MDMA is happening now. How do clinicians feel about this potential treatment for PTSD?

A lead educator and clinical consultant in the Lykos Therapeutics MDMA Therapist Education Program discusses MDMA-assisted therapy’s potential.

Some clinicians are skeptical about the potential of MDMA-assisted therapy...

If approved, how will MDMA-assisted therapy impact clinical psychiatry? The CEO of Lykos Therapeutics shares her thoughts.

In advance of the June 4 FDA Advisory Committee Meeting on MDMA-assisted therapy, we sat down with Alejandra Alva, MD, to get his first impressions.

A poster at the 2024 ASCP Annual Meeting shared data from 3 randomized clinical trials on the safety and tolerability of this treatment combination.

An expert shares highlights from her panel presentation at the 2024 ASCP Annual Meeting.